AstraZeneca plc vs Hershey Co — how do they compare? AstraZeneca plc trades at $168.72 (market cap $253.13B), while Hershey Co trades at $172.07 (market cap $34.78B). The key difference: AstraZeneca plc is far larger — about 7.3× Hershey Co's market cap, and Hershey Co pays the higher dividend (3.39%). Which is the better fit depends on your goals.
| AZN | HSY | |
|---|---|---|
Market Cap | $253.13B | $34.78B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $236.28 |
52-Week Low | $137.44 | $162.31 |
Enterprise Value | $279.37B | $39.58B |
Dividend Yield | 1.92% | 3.39% |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Hershey (HSY) trades at $175.24, up 0.91% on the day, with a bearish technical signal but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, including Q1 2026 EPS of $2.35 versus $2.04 expected. Revenue growth is steady, with 2025 revenue at $11.69 billion, though net income margin compressed to 9.12% from prior years. Analyst consensus price target is $209.25, implying significant upside, supported by a 3.3% dividend yield and recent margin recovery trends.
The outlook for HSY is cautiously optimistic, with earnings momentum and valuation support offset by near-term technical weakness. Investment opportunity lies in continued execution on margin improvement and innovation, such as new REESE'S PIECES products. Key risks include persistent input cost pressures, competitive threats, and macroeconomic sensitivity. Wall Street sentiment is mixed, with 65.7% hold ratings reflecting balanced risk-reward amid recovery phase.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →